Infectious Disease and Microbiology – Dientamoeba fragilis

Overview

Dientamoeba fragilis is an intestinal protozoan found worldwide. Infection is frequently asymptomatic, although some infected individuals develop gastrointestinal symptoms, particularly abdominal pain and diarrhea.

Despite its name and intestinal location, D. fragilis should not be confused with Entamoeba histolytica, the invasive protozoan responsible for amebiasis.

Microbiologic Characteristics

Dientamoeba fragilis is a protozoan parasite that inhabits the human gastrointestinal tract.

Important characteristics include:

• Intestinal protozoan

• Usually identified in its trophozoite form

• Does not cause the invasive amebiasis associated with E. histolytica

Epidemiology

D. fragilis has a worldwide distribution.

The organism can be detected in both symptomatic and asymptomatic individuals, which can make determining its clinical significance challenging in some patients.

Clinical Infection

Most infections are asymptomatic.

When symptomatic disease occurs, gastrointestinal manifestations predominate.

Abdominal Pain

Abdominal discomfort or pain is one of the principal symptoms associated with D. fragilis infection.

The severity and duration can vary considerably among affected individuals.

Diarrhea

Some patients develop diarrhea, which may occur alone or together with abdominal pain.

Other nonspecific gastrointestinal complaints may accompany symptomatic infection.

Distinction from Entamoeba histolytica

An important microbiologic distinction is:

Dientamoeba fragilis ≠ Entamoeba histolytica

E. histolytica causes amebiasis, which can produce invasive colitis and extraintestinal disease such as liver abscess.

D. fragilis, in contrast, is generally associated with asymptomatic intestinal colonization or relatively mild gastrointestinal symptoms.

Diagnosis

Traditional diagnosis is based on microscopic examination of stool specimens.

Diagnostic techniques include:

• Direct stool examination

• Ferrous hematoxylin staining

Because trophozoites can be difficult to recognize, appropriately collected and processed stool specimens are important.

Molecular Diagnosis

Where available, PCR-based stool testing can provide sensitive detection of D. fragilis and may be incorporated into multiplex gastrointestinal parasite testing.

However, a positive result should be interpreted together with the patient’s symptoms because asymptomatic carriage occurs.

Treatment

Treatment is generally considered for patients with compatible gastrointestinal symptoms when D. fragilis is believed to be responsible.

One regimen described in the source is:

Paromomycin 500 mg orally every 8 hours for 7 days

Iodoquinol

Another treatment regimen is:

Iodoquinol 650 mg orally every 8 hours for 20 days

Additional Treatment Options

Other agents historically used include:

Tetracycline for approximately 7–10 days

or

Metronidazole for approximately 7 days

Treatment selection depends on patient factors, availability, tolerance, and the clinical significance of the detected organism.

Asymptomatic Infection

Because D. fragilis frequently occurs without symptoms, detection of the organism does not necessarily establish it as the cause of gastrointestinal complaints.

The decision to treat should therefore consider:

• Presence and severity of symptoms

• Alternative causes of diarrhea or abdominal pain

• Persistence of symptoms

• Other organisms detected in stool

High-Yield Clinical Pattern

Abdominal pain and/or diarrhea

• ●

Intestinal protozoan detected in stool

• ●

No evidence of invasive amebiasis

→ Consider Dientamoeba fragilis

Exam Essentials

Organism: Dientamoeba fragilis

Type: Protozoan parasite

Distribution: Worldwide

Most common course: Asymptomatic infection

Possible symptoms: Abdominal pain and diarrhea

Important distinction: Not Entamoeba histolytica

Traditional diagnosis: Direct stool examination + ferrous hematoxylin stain

Modern diagnostic option: Stool PCR

Treatment options: Paromomycin or iodoquinol

Additional historical therapies: Tetracycline or metronidazole

Key clinical pearl: Dientamoeba fragilis is a worldwide intestinal protozoan that is often asymptomatic but may cause abdominal pain and diarrhea; it should not be confused with the invasive amebiasis caused by Entamoeba histolytica.

Microbiologic Characteristics Dientamoeba fragilis is a protozoan parasite that inhabits the human gastrointestinal tract. Important characteristics include: • Intestinal protozoan

• Usually identified in its trophozoite form

• Does not cause the invasive amebiasis associated with E. histolytica

Epidemiology D. fragilis has a worldwide distribution. The organism can be detected in both symptomatic and asymptomatic individuals, which can make determining its clinical significance challenging in some patients.

Clinical Infection Most infections are asymptomatic. When symptomatic disease occurs, gastrointestinal manifestations predominate.

Abdominal Pain Abdominal discomfort or pain is one of the principal symptoms associated with D. fragilis infection. The severity and duration can vary considerably among affected individuals.

Diarrhea Some patients develop diarrhea, which may occur alone or together with abdominal pain. Other nonspecific gastrointestinal complaints may accompany symptomatic infection.

Distinction from Entamoeba histolytica An important microbiologic distinction is: Dientamoeba fragilis ≠ Entamoeba histolytica E. histolytica causes amebiasis, which can produce invasive colitis and extraintestinal disease such as liver abscess. D. fragilis, in contrast, is generally associated with asymptomatic intestinal colonization or relatively mild gastrointestinal symptoms.

Diagnosis Traditional diagnosis is based on microscopic examination of stool specimens. Diagnostic techniques include: • Direct stool examination

• Ferrous hematoxylin staining Because trophozoites can be difficult to recognize, appropriately collected and processed stool specimens are important.

Molecular Diagnosis Where available, PCR-based stool testing can provide sensitive detection of D. fragilis and may be incorporated into multiplex gastrointestinal parasite testing. However, a positive result should be interpreted together with the patient’s symptoms because asymptomatic carriage occurs.

Treatment Treatment is generally considered for patients with compatible gastrointestinal symptoms when D. fragilis is believed to be responsible. One regimen described in the source is: Paromomycin 500 mg orally every 8 hours for 7 days

Iodoquinol Another treatment regimen is: Iodoquinol 650 mg orally every 8 hours for 20 days

Additional Treatment Options Other agents historically used include: Tetracycline for approximately 7–10 days or Metronidazole for approximately 7 days Treatment selection depends on patient factors, availability, tolerance, and the clinical significance of the detected organism.

Asymptomatic Infection Because D. fragilis frequently occurs without symptoms, detection of the organism does not necessarily establish it as the cause of gastrointestinal complaints. The decision to treat should therefore consider: • Presence and severity of symptoms

• Alternative causes of diarrhea or abdominal pain

• Persistence of symptoms

• Other organisms detected in stool

High-Yield Clinical Pattern Abdominal pain and/or diarrhea  ●  Intestinal protozoan detected in stool  ●  No evidence of invasive amebiasis → Consider Dientamoeba fragilis

Exam Essentials Organism: Dientamoeba fragilis

Type: Protozoan parasite

Distribution: Worldwide

Most common course: Asymptomatic infection

Possible symptoms: Abdominal pain and diarrhea

Important distinction: Not Entamoeba histolytica

Traditional diagnosis: Direct stool examination + ferrous hematoxylin stain

Modern diagnostic option: Stool PCR

Treatment options: Paromomycin or iodoquinol

Additional historical therapies: Tetracycline or metronidazole

Key clinical pearl: Dientamoeba fragilis is a worldwide intestinal protozoan that is often asymptomatic but may cause abdominal pain and diarrhea; it should not be confused with the invasive amebiasis caused by Entamoeba histolytica.